# A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

> **NCT00117039** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 1500 (—)

## Conditions studied

- Anemia
- Neoplasms

## Interventions

- **DRUG:** Aranesp®

## Key facts

- **NCT ID:** NCT00117039
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 1500 (—)
- **Last updated:** 2008-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117039, "A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT00117039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*